Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Remepy secures $36 million in Series A funding to advance its AI-driven Parkinson's treatment, led by O.G. Venture Partners and M Ventures.
PRIVATEAug 12, 2026•about 3 hours ago
Amount Raised
$36 Million
Round Type
Series A
Ramat GanBiotechnologyInvestors
It Farm CorpTadmor GroupPsy Med VenturesFresh FundQumra Capital97212 VenturesTech AvivVine VenturesNfxM VenturesO.G. Venture Partners
Description
Remepy, a developer of hybrid drugs for Parkinson's, has raised $36 million in a Series A round. The financing will support the development of its Hybrid Drug pipeline and advance Phase III clinical trials for its lead program, Hybridopa. Led by O.G. Venture Partners and M Ventures, this funding aims to enhance pharmaceutical partnerships
Don't miss Remepy's next move
Get an email the moment Remepy raises, hires an exec, or expands — usually minutes after it happens.
One email per event. Unsubscribe anytime.
Related People
Suggested for you
1 contactFunding Insights
Based on industry dataTypical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech